Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 107 peer-reviewed journal articles Updated
Pulmonology

Understanding Your IPF Diagnosis

At a Glance

Idiopathic pulmonary fibrosis (IPF) is a progressive disease causing lung tissue to become thick and scarred for unknown reasons. While serious, modern antifibrotic medications like nintedanib and pirfenidone can slow the disease progression by approximately 50%, offering long-term stability.

Receiving a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) can feel like the world has suddenly shifted beneath your feet. It is common to feel a sense of shock, numbness, or deep anxiety after being told you have a progressive, “fatal” condition [1][2]. However, while the diagnosis is serious, the medical landscape for IPF has transformed significantly in recent years. You are not at the end of your journey; you are at the beginning of a managed path where modern medicine and specialized care can offer significant stability.

Understanding Your Diagnosis

Idiopathic Pulmonary Fibrosis (IPF) is a condition characterized by progressive lung scarring (also called fibrosis) [3].

  • Pulmonary refers to the lungs [3].
  • Fibrosis refers to scar tissue, much like the scars that form on your skin after an injury [3].
  • Idiopathic means the exact cause of the scarring is unknown [4].

In a healthy lung, the air sacs are thin and elastic, allowing oxygen to pass easily into your blood. In IPF, this tissue becomes thick, stiff, and scarred [3]. This makes it harder for your lungs to expand and harder for oxygen to reach your bloodstream, which often leads to shortness of breath and a persistent dry cough [5].

Who Does It Affect?

IPF is not a common disease, but it is the most frequent form of pulmonary fibrosis [6]. While incidence rates vary worldwide, it primarily affects:

  • Older Adults: It is most frequently diagnosed in individuals over the age of 60 [7].
  • Men: Statistics show a higher prevalence in men than in women [8].
  • Smokers: A history of smoking is often a common factor among those diagnosed [9].
  • Genetics (Familial IPF): While mostly sporadic, roughly 10-20% of cases are considered familial. If you have siblings or children, you might consider discussing genetic risks with your care team [10].

Three Stabilizing Facts

When the initial shock of the diagnosis hits, it is helpful to anchor yourself with these evidence-based realities:

01

The Standard of Care: Managing and Slowing IPF

Learn about the standard of care for Idiopathic Pulmonary Fibrosis (IPF), including antifibrotic medications, supplemental oxygen, and lung transplants.

02

Prognosis and Measuring Progress

Learn how Idiopathic Pulmonary Fibrosis (IPF) progress is measured. Understand the GAP Index, FVC lung function tests, survival rates, and acute exacerbations.

03

Building Your Expert Care Team

Learn how to build an expert Idiopathic Pulmonary Fibrosis (IPF) care team. Discover why you need an ILD specialist, what to bring, and questions to ask.

Navigating the Road Ahead

The goal of modern IPF care is to protect the lung function you have and maintain your quality of life for as long as possible [18]. Early intervention is key; starting treatment soon after diagnosis has been shown to help forestall the disease’s progression [19][20].

Beyond medication, your care team may suggest pulmonary rehabilitation (specialized exercise and education) and symptom management to help you stay active and engaged with your life [21][22]. You can read more about living well in Quality of Life and Symptom Management. Remember, a diagnosis is a data point, not a destiny—and today’s medical advancements provide more reasons for hope than ever before.

Common questions in this guide

What does an idiopathic pulmonary fibrosis (IPF) diagnosis mean?
IPF is a condition where the lung tissue becomes progressively thick, stiff, and scarred over time. The term "idiopathic" means that the exact cause of this scarring is currently unknown.
Can idiopathic pulmonary fibrosis be managed?
While IPF is a serious and progressive disease, modern medicine has transformed how it is managed. Many patients experience long periods of stability and live longer today thanks to early treatment and therapies that slow the scarring process.
What treatments are available for idiopathic pulmonary fibrosis?
The primary treatments are antifibrotic medications, such as nintedanib and pirfenidone, which can slow the decline of lung function by about 50 percent. Doctors also frequently recommend pulmonary rehabilitation to help maintain lung capacity and improve quality of life.
Should I see a specialist for an IPF diagnosis?
Yes, it is highly recommended to receive care at a specialized Interstitial Lung Disease (ILD) center. A multidisciplinary team of pulmonologists, radiologists, and pathologists can provide a more accurate diagnosis and a better long-term management plan.
Is idiopathic pulmonary fibrosis hereditary?
Most cases of IPF occur randomly, but about 10 to 20 percent of cases are considered familial. If you have blood relatives with pulmonary fibrosis or other lung scarring diseases, you should discuss potential genetic risks with your care team.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a candidate for antifibrotic medications like nintedanib or pirfenidone to help slow the scarring in my lungs?
  2. 2.Can you refer me to a specialized Interstitial Lung Disease (ILD) center of excellence for a multidisciplinary review of my case?
  3. 3.Based on my current lung function, what is my specific risk score or 'GAP index'?
  4. 4.What lifestyle changes or pulmonary rehabilitation programs can help me maintain my current lung capacity?
  5. 5.What is your experience in managing patients with IPF, and how often will we monitor my progression?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Current approaches to the management of idiopathic pulmonary fibrosis.

    Raghu G, Richeldi L

    Respiratory medicine 2017; (129()):24-30 doi:10.1016/j.rmed.2017.05.017.

    PMID: 28732832
  2. 2

    Idiopathic pulmonary fibrosis: What nurses need to know.

    Pruitt B

    Nursing 2021; (51(1)):22-29 doi:10.1097/01.NURSE.0000724352.48335.1b.

    PMID: 33346613
  3. 3

    Interleukin-11 causes alveolar type 2 cell dysfunction and prevents alveolar regeneration.

    Ng B, Huang KY, Pua CJ, et al.

    Nature communications 2024; (15(1)):8530 doi:10.1038/s41467-024-52810-8.

    PMID: 39358385
  4. 4

    Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.

    Jo HE, Troy LK, Keir G, et al.

    Respirology (Carlton, Vic.) 2017; (22(7)):1436-1458 doi:10.1111/resp.13146.

    PMID: 28845557
  5. 5

    Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives.

    Graney BA, Lee JS

    Patient related outcome measures 2018; (9()):321-328 doi:10.2147/PROM.S144425.

    PMID: 30288134
  6. 6

    Idiopathic pulmonary fibrosis: another step in understanding the burden of this disease.

    Hutchinson J

    The European respiratory journal 2016; (48(1)):26-8 doi:10.1183/13993003.00907-2016.

    PMID: 27365508
  7. 7

    Sex Differences in the Incidence and Outcomes of Patients Hospitalized by Idiopathic Pulmonary Fibrosis (IPF) in Spain from 2016 to 2019.

    López-Muñiz Ballesteros B, López-Herranz M, Lopez-de-Andrés A, et al.

    Journal of clinical medicine 2021; (10(16)) doi:10.3390/jcm10163474.

    PMID: 34441772
  8. 8

    Epidemiology of idiopathic pulmonary fibrosis: a population registry-based study.

    Francesca G, Michele S, Anna P, et al.

    Orphanet journal of rare diseases 2026; (21(1)):57 doi:10.1186/s13023-026-04210-y.

    PMID: 41555350
  9. 9

    Global incidence and prevalence of idiopathic pulmonary fibrosis.

    Maher TM, Bendstrup E, Dron L, et al.

    Respiratory research 2021; (22(1)):197 doi:10.1186/s12931-021-01791-z.

    PMID: 34233665
  10. 10

    Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis.

    Baratella E, Ruaro B, Giudici F, et al.

    Diagnostics (Basel, Switzerland) 2021; (11(5)) doi:10.3390/diagnostics11050762.

    PMID: 33922858
  11. 11

    Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease.

    Hoffmann-Vold AM, Weigt SS, Saggar R, et al.

    EBioMedicine 2019; (50()):379-386 doi:10.1016/j.ebiom.2019.10.050.

    PMID: 31732480
  12. 12

    Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis.

    Mei Q, Liu Z, Zuo H, et al.

    Frontiers in pharmacology 2021; (12()):797292 doi:10.3389/fphar.2021.797292.

    PMID: 35126134
  13. 13

    Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives.

    Kreuter M, Bonella F, Wijsenbeek M, et al.

    BioMed research international 2015; (2015()):329481 doi:10.1155/2015/329481.

    PMID: 26779535
  14. 14

    Pharmacological management of IPF.

    Borie R, Justet A, Beltramo G, et al.

    Respirology (Carlton, Vic.) 2016; (21(4)):615-25 doi:10.1111/resp.12778.

    PMID: 27072575
  15. 15

    Epidemiology of Idiopathic Pulmonary Fibrosis in Northern Italy.

    Harari S, Madotto F, Caminati A, et al.

    PloS one 2016; (11(2)):e0147072 doi:10.1371/journal.pone.0147072.

    PMID: 26841042
  16. 16

    Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis.

    Kropski JA, Blackwell TS

    Annual review of medicine 2019; (70()):211-224 doi:10.1146/annurev-med-041317-102715.

    PMID: 30691371
  17. 17

    Russian Registry of Idiopathic Pulmonary Fibrosis: Clinical Features, Treatment Management, and Outcomes.

    Chikina S, Cherniak A, Merzhoeva Z, et al.

    Life (Basel, Switzerland) 2023; (13(2)) doi:10.3390/life13020435.

    PMID: 36836792
  18. 18

    Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.

    Mackintosh JA, Keir G, Troy LK, et al.

    Respirology (Carlton, Vic.) 2024; (29(2)):105-135 doi:10.1111/resp.14656.

    PMID: 38211978
  19. 19

    Idiopathic Pulmonary Fibrosis.

    Lederer DJ, Martinez FJ

    The New England journal of medicine 2018; (378(19)):1811-1823 doi:10.1056/NEJMra1705751.

    PMID: 29742380
  20. 20

    Gender-age-physiology stage and body mass index are useful predictors of nintedanib discontinuation and prognosis in patients with idiopathic pulmonary fibrosis and progressive fibrotic interstitial lung diseases.

    Yazaki K, Matsuyama M, Satoh H, et al.

    BMC pulmonary medicine 2025; (25(1)):564 doi:10.1186/s12890-025-04048-3.

    PMID: 41351144
  21. 21

    Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial.

    Wu Z, Spencer LG, Banya W, et al.

    The Lancet. Respiratory medicine 2024; (12(4)):273-280 doi:10.1016/S2213-2600(23)00432-0.

    PMID: 38237620
  22. 22

    Epidemiology and Prognostic Significance of Cough in Fibrotic Interstitial Lung Disease.

    Khor YH, Johannson KA, Marcoux V, et al.

    American journal of respiratory and critical care medicine 2024; (210(8)):1035-1044 doi:10.1164/rccm.202311-2101OC.

    PMID: 38536110

This page provides general educational information about idiopathic pulmonary fibrosis (IPF). It is not a substitute for professional medical advice, so always consult your pulmonologist about your specific condition and treatment plan.

Get notified when new evidence is published on Idiopathic pulmonary fibrosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.